[ad_1] CBL-514, the world’s first investigational drug for large-area localized fat reduction, has demonstrated significant efficacy in its second and the last Phase 2b study (CBL-0205) before Phase 3. 54.2% of participants in the CBL-514 […]
Tag: Caliway Biopharmaceuticals
Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices
[ad_1] NEW TAIPEI CITY, Dec. 6, 2024 /PRNewswire/ — Caliway Biopharmaceuticals Co., Ltd. (TWSE-6919) is proud to announce its inclusion in the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries […]
Caliway Successfully Lists on Taipei Exchange Following IPO
[ad_1] NEW TAIPEI CITY, Oct. 2, 2024 /PRNewswire/ — Caliway Biopharmaceuticals (Caliway) announced the successful completion of its initial public offering (IPO) and up-listing from the Emerging Stock Market to the Taipei Exchange (TWSE-6919). The […]
Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum’s Disease
[ad_1] NEW TAIPEI CITY, Sept. 3, 2024 /PRNewswire/ — Caliway Biopharmaceuticals (Caliway) announced that the subject recruitment of CBL-514 Phase 2b study for Dercum’s disease (CBL-0202 DD Phase 2b study, NCT06303570) has been initiated. The […]
